Literature DB >> 7507842

The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology.

H Stoiber1, N M Thielens, C Ebenbichler, G J Arlaud, M P Dierich.   

Abstract

gp41, the transmembrane glycoprotein of HIV-1, has been shown to be non-covalently associated with gp120. We have shown that it also binds human C1q. To analyze the interaction site(s) of gp41 with these two molecules, we established an enzyme-linked immunosorbent assay (ELISA) system using recombinant soluble gp41 [amino acids (aa) 539-684] and peptides thereof. In the cell-external part of gp41 three sites (aa 526-538, aa 590-613 and aa 625-655) were found to bind both gp120 and C1q. That gp120 and C1q use the same sites was evidenced by the fact that these proteins competed with each other for the same sites in recombinant soluble gp41 and gp41 peptides. It could be demonstrated by ELISA, that rabbit antibodies against human C1q recognized gp120, and rabbit antibodies against gp120 cross-reacted with C1q. Rabbit anti-gp120, HIV-1-positive human sera and anti-gp120 obtained from such sera agglutinated sensitized sheep erythrocytes with human C1q (EAC1q). These data suggest that in addition to functional homology between C1q and gp120 structural homology between these two molecules exists. This molecular mimicry might become the basis for immunologically relevant autoimmune phenomena.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507842     DOI: 10.1002/eji.1830240203

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

Review 1.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

2.  Oligoclonal T cells are infiltrating the brains of children with AIDS: sequence analysis reveals high proportions of identical beta-chain T-cell receptor transcripts.

Authors:  W L Lin; J E Fincke; L R Sharer; D S Monos; S Lu; J Gaughan; C D Platsoucas; E L Oleszak
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 3.  Enhancing role of complement in HIV infection.

Authors:  A Mouhoub; N Thieblemont; C Delibrias; E Fischer; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

4.  Serologic reactivity of a synthetic peptide from human immunodeficiency virus type 1 gp41 with sera from a Mexican population.

Authors:  G Gevorkian; C Soler; M Viveros; A Padilla; T Govezensky; C Larralde
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

5.  Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Authors:  Zoltán Prohászka; Ferenc D Tóth; Dénes Bánhegyi; George Füst
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

6.  Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.

Authors:  Z Prohászka; T Hidvégi; E Ujhelyi; H Stoiber; M P Dierich; C Süsal; G Füst
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

7.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Authors:  Suzanne Willey; Marlén M I Aasa-Chapman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Robin A Weiss; Stuart J D Neil
Journal:  Retrovirology       Date:  2011-03-14       Impact factor: 4.602

8.  Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection.

Authors:  Michael Huber; Marek Fischer; Benjamin Misselwitz; Amapola Manrique; Herbert Kuster; Barbara Niederöst; Rainer Weber; Viktor von Wyl; Huldrych F Günthard; Alexandra Trkola
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

9.  Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells.

Authors:  Wilfried Posch; Marion Steger; Ulla Knackmuss; Michael Blatzer; Hanna-Mari Baldauf; Wolfgang Doppler; Tommy E White; Paul Hörtnagl; Felipe Diaz-Griffero; Cornelia Lass-Flörl; Hubert Hackl; Arnaud Moris; Oliver T Keppler; Doris Wilflingseder
Journal:  PLoS Pathog       Date:  2015-06-29       Impact factor: 6.823

10.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).

Authors:  H Stoiber; C Pintér; A G Siccardi; A Clivio; M P Dierich
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.